MyoKardia Inc

MyoKardia — Investor Presentation (March 2016)

28 slides from MyoKardia's investor presentation, Mar 8, 2016

  1. Slide 1: Pioneering Precision Cardiovascular Medicine – Corporate Presentation March 2016

    Exhibit 99.1 Pioneering (NASDAQ: Corporate March 2016Presentation Precision MYOK) Cardiovascular Medicine

  2. Slide 2: Safe-Harbor Forward Looking Statements

    Safe-Harbor This regarding statements. and Accordingly, events affect 2015 2looking phrases presentation pursuant these could statements, our The forward-looking or and differ we strategy, to similar words may Forward Rule contains materially whether not expressions 424(b)(4), “anticipate,” future a

  3. Slide 3: Investment Highlights

    Investment Applying population Lead proof DCM-1 studies; Important research Strong 3runway product ofcash through initiate candidate mechanism; and precision disease segmented Highlights position our candidate Phase multiple platform insights selected medicine from initiate 1into MYK-461 invalue IPO

  4. Slide 4: Our Purpose: Rethinking Cardiovascular Disease

    14Our Rethinking Significant CARDIOMYOPATHIES HERITABLE Rare, Chronic Cause HCM, No genetically addressstroke and million+ approved Purpose: DCM unmet Cardiovascular debilitating and underlying most driven death afflicted need therapies to improve common disease in to theDisease U.S. of patients and

  5. Slide 5: Proven, Experienced Leadership Team

    Proven Experienced Tassos Robert Chief Jake VP, Ingrid Michael Joseph SVP, Pharmaceutical Continued Leslie BioFrontiers Christine Hospital; Jonathan Harvard James Stanford Charles Third Demonstrated 5Integral Business Bauer Drug Human Nonclinical Rock Executive Medical Leinwand, Boyes Spudich, Giana

  6. Slide 6: Rapid Creation of First-in-Class Targeted Therapies Pipeline

    Rapid US Program Obstructive Non-Obstructive MYK-461: Heritable DCM-1: Additional HCM-2: RCM, LUS-1: DCM Current 6Anticipated Ex-US subtypes Creation additional Stage Discovery DCM HCM Near-Term HCMofHCM HCM, subtype Pipeline Preclinical Development of First-in-Class Phase Path 1 Phase Targeted 2 ri

  7. Slide 7: MyoKardia's Precision Medicine Platform

    MyoKardia’s Precision Mechanism Efficient Clinical Specifically causality In groups animals Imaging-based smaller, 7biomarker vitro Small animals more insight clinical (genetics) medicine strategy conserved Platform: cost- Large Potential tovolunteers development Molecular effective approach inHealt

  8. Slide 8: MyoKardia Has World-class Collaborators

    MyoKardia Has World-class 8collaborators academic …and Created growing 10the centers, World’s clinical 10,000+ Leading insights patients HeartNovel Disease genetic Registry and

  9. Slide 9: Large Patient Population Segmented into Subgroups

    Largefigures (All Segment (70,000) Segments(410,000)(630,000) HCM Segments(220,000) Segments(100,000) Segments(300,000) Patient Other Obstructive, DCM symptomatic, ISM+ 9Initial Affected HCM Non- Patient DCM (30,000) (12,000)(1 ISM- target Obstructive #1 approximate, #2 segment(s) Obstructive, sympt

  10. Slide 10: Three Distinct Types of Cardiac Muscle Disruptions

    Cardiomyopathies Hypertrophic Normal contraction 10 heart(HCM)(DCM) Excessive contraction cardiomyopathy Impaired Result relaxation from Inadequate Dilated Three contraction Distinct cardiomyopathy Types of Cardiac Muscle Disruptions

  11. Slide 11: Cardiac Muscle Disruptions Caused by Defective Contractile Proteins

    Cardiac Heart Normal Actin Actin-myosin Myosin Force-producing 11 Muscle thin Sarcomere thick Muscle filament filament Fibers cross-bridge Disruptions myosin Myofibril head Caused by Defective Contractile Proteins

  12. Slide 12: Our Product Candidates Designed to Correct Causal Defects

    Our few Normal ~25% HCM DCM Too 12 many Product Sarcomere cross-bridges Sarcomere engaged engaged Candidates cross-bridges cross-bridges engaged are Designed to Correct the Underlying Causal Defects

  13. Slide 13: Hypertrophic Cardiomyopathy: Devastating Disease, No Approved Therapies

    Hypertrophic Disease Chronic, Shortness Increased Standard No Non-targeted Advanced Invasive Normal Obstruction ventricular thickening Hypertrophy: a(LVOT) (1) myectomy, 13characteristic Surgical approved Heart Burden interventions(1) progressive, of risk of disease of outflow use Care of or breath,

  14. Slide 14: Detail on HCM Initial Target Population

    Detail HCM An muscle Measured pressure Degree interventions Estimate Initial (symptomatic Compare oHCM Well-established outcomes Relief improvement (1) function(3) et myotomy-myectomy 14 al. Ommen, additional “Effect Heart target on of Patients obstructs ofgradient 65%+ obstruction to Obstructive fo

  15. Slide 15: MYK-461: First Oral Drug Candidate for HCM

    Drug First Oral be Allosteric Early Reduces contraction expected Streamlined program If underlying many 15 MYK-461 ross-bridges approved, studied small drug Properties biomarker engaged proof overall nearing to modulator Reduce Has molecule cause biomechanical CV development first target of Demonstr

  16. Slide 16: Reducing Contractility to Reduce Obstruction

    Reducing Reduce Improved muscle Agents outcomes Obstructive Relief (1) R., (3) European 16 Nistri Firoozi, Losi, ofcontractility that cardiac M. obstruction et Heart Contractility S. reduce al. HCM A.,et Am Alleviate et Journal al.increases al. contractility J“Septal pressure Cardiol. documented (20

  17. Slide 17: Growing Evidence of MYK-461 Mechanism

    Growing Reduce Improved amuscle S outcomes Human animal Large disease Science Feb HCM New MYK-461 demonstrates of and Top-line Oct 17 nimal mechanism reverses HCM 2015 2016 data mice felines contractility in cardiac paper results Evidence study LVOT today patients prevents Phase studies proof MYK-46

  18. Slide 18: Science Publication: Disease Prevention and Reversal in Mice

    Science Experiment Design Commentary Disease “A Untreated Mouse 18 small-molecule Heart /Publication Prevention Prevent HCM Multiple Mouse Reverse Treated development inhibitor Disease in Heart established LV February HCM hypertrophy Reversal ofof sarcomere 2016: genetic LV hypertrophy Prevention on

  19. Slide 19: MYK-461 Dose-Dependent Relief of Obstruction in Felines

    (n=3)(n=5) MYK-461 Maine and Experiment Design Conclusions: Commentary Results Gradient 4Vehicle naLVOT Me in uction Red systolic coon 0/to Dose-Dependent -20 e) 1.0 r(delativ 0Gra 0.0 [MYK-461] Relief Untreated See 19 ient =-4 Gra 200 0.8 ient 0.88 (mmHg) also: 0.2 -16 d0.6 0.4 -12 400 of -8MYK-461

  20. Slide 20: MYK-461: Clinical Development Plan

    (1) MYK-461: Type Healthy (± dose HV HCM Symptomatic Phase obstructive Ph1 Ph2a Ph2b Open Near-Term Ongoing Completed LEGEND Today 20 obstructive) Single Multiple SAD MAD (SAD) (MAD) Study –Label patients (oHCM) 2Mid-2016 oHCM nHCM ~100(1) volunteers Current ~16(1) trial trial Plan ascending HCM Rar

  21. Slide 21: Clinical Update: Phase 1 Data in Healthy Volunteers and Patients

    Clinical Healthy (% HCM )P orf0egnhsal(% Im C V O -T B L Update: ~16 To Topline 21 irP inC —2 —3 a—1 la 2a1o3include 2a3o0s0 hcHCM 0tie 00heC oe0Patient P0lin obrt odata nVolunteer 001 Proof arto(H oh5—2 tetie patients; 96mg 1—4 4—1 6(H o2(Patient expected rt nSAD V hoft46—4 V r)2—4 82Mechanism and

  22. Slide 22: Potential Registration Endpoints in oHCM

    Potential Relief LVOT Severe Obstruction Chief Dyspnea Score decompensated NYHA Class Improvement physicians Peak during pVO2 late-stage Endpoint Exercise Treadmill Testing Measure based Basis 6MWT Additional diseases 22 O2 Qualitative for presenting scale: on of Determines Direct exercise obstructi

  23. Slide 23: MYK-461 Phase 1 Study Descriptions

    MYK-461 Phase Description Study Completed ‘002: placebo) measured independent Ongoing; complete ~16 patients ‘001: HCM To Topline cohorts Ongoing dose ‘003: Healthy Volunteers state 23 include HCM serum levels SAD MAD Patients 1todata Conclusions dependent Date mechanism Tolerability mechanism enrol

  24. Slide 24: Dilated Cardiomyopathy: Devastating Disease, No Approved Therapies

    Dilated Burden Chronic, failure Shortness interfere Increased heart Standard No underlying Non-targeted Advanced Invasive Normal Improper and pumped thin-walled Hypocontractility: characteristic (1) 24 While approved insufficient transplant that Cardiomyopathy: of Heart by with interventions(1) prog

  25. Slide 25: DCM-1: First Oral Drug Candidate for DCM

    DCM-1: Drug First Oral Allosteric Increases contraction medicine If underlying few 25 DCM-1 ross-bridges approved, engaged small drug Properties Pre-Clinical approach overall to modulator molecule cause biomechanical expected, first target Clinical force targeted ofan DCM genetic of Candidates based

  26. Slide 26: Previous and New Animal Data on DCM-1

    Previous In New Animal output IIncreases V T gnahsve.lin % C B DCM-1 Vehicle 265210—1 —5 awild-type 05s Large e0while lin Data Development Candidate Small Stroke ebalanced 3dogs, reducing invasive Predicts h In 6Volume hwild-type DCM-1 (1decrease mg/kg) that imaging Candidate elevated increasing can

  27. Slide 27: Multiple Near-Term Catalysts

    Multiple 2016 H1 Release data SAD Initiate Mid-2016: Q2 Top-line Phase HCM volunteers MYK-461 DCM-1 27 2016: for 2017 trial patients 1DCM-1 Phase SAD of compound data Near-Term Top-line inpatients H1 milestone final H2healthy for trial 2017: in 12016: healthy Phase in data milestone Data Phase for 1

  28. Slide 28: Our Culture and Core Values

    Our Culture and Core Values 28

MyoKardia — Investor Presentation (March 2016) on 6ix